Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	39.01	31.64	21.25	21.83	0.04
Revenue Growth (YoY)	23.29%	48.90%	-2.66%	55879.49%	-95.93%
Cost of Revenue	15.6	10.58	6.93	2.83	0.44
Gross Profit	23.41	21.06	14.32	19.01	-0.4
Selling, General & Admin	22.34	18.93	18.58	14.27	12.67
Research & Development	3.26	3.32	4	6.23	14.05
Operating Expenses	25.59	22.25	22.58	20.5	26.71
Operating Income	-2.18	-1.19	-8.26	-1.5	-27.11
Interest Expense	-2.01	-1.06	-0.96	-1.04	-0.88
Interest & Investment Income	0.79	1.56	0.19	0.04	0.03
EBT Excluding Unusual Items	-3.39	-0.69	-9.02	-2.5	-27.97
Merger & Restructuring Charges	-0.42	-	-	-	-
Gain (Loss) on Sale of Assets	-	-	-	0.18	-
Other Unusual Items	-	-	-	0.37	-
Pretax Income	-3.81	-0.69	-9.02	-1.96	-27.97
Income Tax Expense	0.02	0.25	-	-	-
Net Income	-3.82	-0.94	-9.02	-1.96	-27.97
Net Income to Common	-3.82	-0.94	-9.02	-1.96	-27.97
Shares Outstanding (Basic)	26	26	25	25	21
Shares Outstanding (Diluted)	26	26	25	25	21
Shares Change (YoY)	0.97%	1.99%	-0.24%	19.98%	18.30%
EPS (Basic)	-0.15	-0.04	-0.36	-0.08	-1.33
EPS (Diluted)	-0.15	-0.04	-0.36	-0.08	-1.33
Free Cash Flow	0.94	6.82	4.78	-4.73	-22.4
Free Cash Flow Per Share	0.04	0.27	0.19	-0.19	-1.07
Gross Margin	60.01%	66.56%	67.38%	87.05%	-
Operating Margin	-5.59%	-3.77%	-38.87%	-6.85%	-69515.39%
Profit Margin	-9.80%	-2.96%	-42.45%	-8.96%	-71717.95%
Free Cash Flow Margin	2.42%	21.54%	22.51%	-21.66%	-57425.64%
EBITDA	-1.11	-0.36	-6.55	-1.12	-26.59
EBITDA Margin	-2.83%	-1.13%	-30.81%	-5.13%	-
D&A For EBITDA	1.08	0.83	1.71	0.37	0.52
EBIT	-2.18	-1.19	-8.26	-1.5	-27.11
EBIT Margin	-5.59%	-3.77%	-38.87%	-6.85%	-
Revenue as Reported	39.01	31.64	21.25	21.83	0.04

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q